Interim results of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in patients with NSCLC in a phase 1 trial.
Elisa Fontana(Sarah Cannon Research Institute), Ramy Saleh(McGill University Health Centre), Kaïssa Ouali(Institut Gustave Roussy), Nuria Kotecki(Centre Oscar Lambret), Sebastian Ochsenreither(Heidelberg University), Afshin Dowlati(University Hospitals of Cleveland), Justin Call, Amita Patnaik(South Texas Accelerated Research Therapeutics), Anna Minchom(Royal Marsden NHS Foundation Trust), Neeltje Steeghs(University Medical Center Utrecht), Maura L. Gillison(The University of Texas MD Anderson Cancer Center), Jonathan W. Riess(University of California Davis Medical Center), Anna Spreafico(University Health Network), Paula Sàbat(Institut Català d'Oncologia), Shivani Gupta(Seagen (United States)), Rong Zhang(China Medical University), Andrea Zivi(Royal Marsden NHS Foundation Trust), Elena Garralda(Vall d'Hebron Hospital Universitari), Christophe Le Tourneau(Institut Curie), Aakash Desai(Jacksonville College)
Cited by 2
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k
Incidence Trends for Human Papillomavirus–Related and –Unrelated Oral Squamous Cell Carcinomas in the United States
|Journal of Clinical Oncology|2008|1.6k